http://purl.org/np/RAkrbzE_O5... RAkrbzE_O5

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-06-12T14:20:36.100Z

http://purl.org/np/RAkrbzE_O5... RAkrbzE_O5

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

alimta r in combination with pembrolizumab and platinum chemotherapy for the initial treatment of patients with metastatic non squamous nsclc with no egfr or alk genomic tumor aberrations 1 1 in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non squamous non small cell lung cancer nsclc 1 1 as a single agent for the maintenance treatment of patients with locally advanced or metastatic non squamous nsclc whose disease has not progressed after four cycles of platinum based first line chemotherapy 1 1 as a single agent for the treatment of patients with recurrent metastatic non squamous nsclc after prior chemotherapy 1 1 limitations of use 1 1 initial treatment in combination with cisplatin of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery 1 2 alimta r in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non squamous non small cell lung cancer nsclc as a single agent for the maintenance treatment of patients with locally advanced or metastatic non squamous nsclc whose disease has not progressed after four cycles of platinum based first line chemotherapy as a single agent for the treatment of patients with recurrent metastatic non squamous nsclc after prior chemotherapy limitations of use see clinical studies 14 1 alimta is indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery

Leoni Bücken

2021-06-12T14:20:36.100Z

http://purl.org/np/RAkrbzE_O5... RAkrbzE_O5

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_7474 DOID_7474

Leoni Bücken

2021-06-12T14:20:36.100Z

http://purl.org/np/RAkrbzE_O5... RAkrbzE_O5

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-06-12T14:20:36.100Z

http://purl.org/np/RAkrbzE_O5... RAkrbzE_O5

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB00642 drugbank:DB00642

Leoni Bücken

2021-06-12T14:20:36.100Z

http://purl.org/np/RAkrbzE_O5... RAkrbzE_O5

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-06-12T14:20:36.100Z

http://purl.org/np/RAkrbzE_O5... RAkrbzE_O5

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-06-12T14:20:36.100Z

http://purl.org/np/RAkrbzE_O5... RAkrbzE_O5

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://schema.org/TreatmentIndication TreatmentIndication

Leoni Bücken

2021-06-12T14:20:36.100Z